These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 10519976)
41. VIP and PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Dalsgaard T; Hannibal J; Fahrenkrug J; Larsen CR; Ottesen B Regul Pept; 2003 Feb; 110(3):179-88. PubMed ID: 12573798 [TBL] [Abstract][Full Text] [Related]
42. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on the cardiovascular system in sheep. Sawangjaroen K; Dallemagne CR; Cross RB; Curlewis JD Peptides; 1992; 13(5):1029-32. PubMed ID: 1480509 [TBL] [Abstract][Full Text] [Related]
43. The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. Wang HY; Jiang XM; Ganea D J Neuroimmunol; 2000 Apr; 104(1):68-78. PubMed ID: 10683516 [TBL] [Abstract][Full Text] [Related]
44. PACAP and VIP differentially preserve neurovascular reactivity after global cerebral ischemia in newborn pigs. Lenti L; Zimmermann A; Kis D; Oláh O; Tóth GK; Hegyi O; Busija DW; Bari F; Domoki F Brain Res; 2009 Aug; 1283():50-7. PubMed ID: 19538945 [TBL] [Abstract][Full Text] [Related]
45. Hemodynamic actions of systemically injected pituitary adenylate cyclase activating polypeptide-27 in the rat. Whalen EJ; Johnson AK; Lewis SJ Eur J Pharmacol; 1999 Jan; 365(2-3):205-15. PubMed ID: 9988104 [TBL] [Abstract][Full Text] [Related]
46. The stimulatory effect of VIP and PACAP on adrenal aldosterone release. Radzikowska M; Wasilewska-Dziubińska E; Baranowska B Ann N Y Acad Sci; 1998 Dec; 865():482-5. PubMed ID: 9928055 [No Abstract] [Full Text] [Related]
47. Effect of VIP and PACAP on vascular and luminal release of serotonin from isolated perfused rat duodenum. Fujimiya M; Yamamoto H; Kuwahara A Ann N Y Acad Sci; 1998 Dec; 865():495-502. PubMed ID: 9928058 [TBL] [Abstract][Full Text] [Related]
48. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo. Warren JB; Larkin SW; Coughlan M; Kajekar R; Williams TJ Br J Pharmacol; 1992 Jun; 106(2):331-4. PubMed ID: 1393266 [TBL] [Abstract][Full Text] [Related]
49. Pituitary adenylate cyclase-activating polypeptide induces hyperthermia in the rat. Pataki I; Adamik A; Jászberényi M; Mácsai M; Telegdy G Neuropharmacology; 2000 Apr; 39(7):1303-8. PubMed ID: 10760372 [TBL] [Abstract][Full Text] [Related]
54. Contractility of retinal pericytes grown on silicone elastomer substrates is through a protein kinase A-mediated intracellular pathway in response to vasoactive peptides. Markhotina N; Liu GJ; Martin DK IET Nanobiotechnol; 2007 Jun; 1(3):44-51. PubMed ID: 17506596 [TBL] [Abstract][Full Text] [Related]
55. Region-specific regulation of neurogenesis by VIP and PACAP: direct and indirect modes of action. DiCicco-Bloom E Ann N Y Acad Sci; 1996 Dec; 805():244-56; discussion 256-8. PubMed ID: 8993407 [No Abstract] [Full Text] [Related]
56. Short- and long-term regulation of tyrosine hydroxylase in chromaffin cells by VIP and PACAP. Haycock JW Ann N Y Acad Sci; 1996 Dec; 805():219-30; discussion 230-1. PubMed ID: 8993405 [TBL] [Abstract][Full Text] [Related]
57. Opposing roles of cyclic AMP in the vascular control of edema formation. Warren JB; Wilson AJ; Loi RK; Coughlan ML FASEB J; 1993 Nov; 7(14):1394-400. PubMed ID: 7693536 [TBL] [Abstract][Full Text] [Related]
58. Comparative effects of ACTH, PACAP, and VIP on fetal human adrenal cells. Chamoux E; Breault L; LeHoux JG; Gallo-Payet N Endocr Res; 1998; 24(3-4):943-6. PubMed ID: 9888602 [TBL] [Abstract][Full Text] [Related]
59. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions. Delgado M; Garrido E; de la Fuente M; Gomariz RP Peptides; 1996; 17(7):1097-105. PubMed ID: 8959742 [TBL] [Abstract][Full Text] [Related]